Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) traded up 3.9% during mid-day trading on Friday . The company traded as high as $22.68 and last traded at $22.36. 11,810 shares changed hands during trading, a decline of 95% from the average session volume of 215,169 shares. The stock had previously closed at $21.53.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised Pulse Biosciences to a "sell" rating in a research note on Tuesday, August 6th.
View Our Latest Stock Analysis on PLSE
Pulse Biosciences Stock Performance
The stock has a market capitalization of $1.32 billion, a PE ratio of -26.52 and a beta of 1.75. The business's 50-day moving average is $15.19 and its two-hundred day moving average is $11.33.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company's stock worth $7,379,000 after acquiring an additional 189,227 shares in the last quarter. Griffin Asset Management Inc. increased its holdings in Pulse Biosciences by 15.7% in the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company's stock valued at $2,616,000 after buying an additional 40,700 shares in the last quarter. Westside Investment Management Inc. boosted its stake in shares of Pulse Biosciences by 97.8% during the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company's stock valued at $712,000 after acquiring an additional 31,440 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock worth $570,000 after purchasing an additional 9,639 shares during the last quarter. Finally, Inspire Investing LLC raised its stake in Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company's stock worth $360,000 after purchasing an additional 10,039 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
